Eruptive nevi under tocilizumab: first case report and data analysis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.14784
Abstract: By this method, the maximum possible DPASI is 40. We have used this scoring system in our ADMH patients and have observed that higher scores correlate with poor prognosis (Fig. 1b–e). Another important factor to… read more here.
Keywords: disease new; new lesions; disease; area ... See more keywords
Soluble PD-L1 as an early marker of progressive disease on nivolumab
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003527
Abstract: Background Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in numerous solid tumors. We determined sPD-L1 levels before and during nivolumab treatment in two prospective clinical trials of metastatic clear cell renal cell carcinoma… read more here.
Keywords: treatment; progressive disease; disease; rcc ... See more keywords
Abstract 4384: Does progressive disease justify pembrolizumab discontinuation: a simulation analysis
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4384
Abstract: Background: With checkpoint inhibition becoming first line therapy in several cancer indications, there is a growing number of patients that are refractory to PD1 therapy. It is unclear if these patients should remain on PD1… read more here.
Keywords: justify pembrolizumab; progression; virtual patients; progressive disease ... See more keywords
Abstract PO-131: Inter-tumoral heterogeneity of progressive disease in melanoma patients treated with pembrolizumab
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.tumhet2020-po-131
Abstract: Introduction: In clinical trials of patients treated with pembrolizumab, RECIST-defined progressive disease (PD) is often assumed to reflect generalized lack or loss of efficacy. However, mixed lesion-level responses within a given patient may reflect more… read more here.
Keywords: heterogeneity; treated pembrolizumab; level; progressive disease ... See more keywords
Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116881
Abstract: The mechanisms of HMA failure in MDS remain unclear, as recent advances in sequencing approaches did not enable the molecular characterization of the cells that survive therapy and drive resistance and disease progression. Here, through… read more here.
Keywords: pattern mds; progressive disease; mds patients; mds ... See more keywords
Conventional MRI Criteria to Differentiate Progressive Disease From Treatment-Induced Effects in High-Grade (WHO Grade 3–4) Gliomas
Sign Up to like & getrecommendations! Published in 2022 at "Neurology"
DOI: 10.1212/wnl.0000000000200359
Abstract: Background and Objectives Posttreatment radiologic deterioration of an irradiated high-grade (WHO grade 3–4) glioma (HGG) may be the result of true progressive disease or treatment-induced effects (TIE). Differentiation between these entities is of great importance… read more here.
Keywords: disease; enhancement; progressive disease; conventional mri ... See more keywords
Progressive Disease in Sentinel-negative Melanoma Patients: Biological Differences and Importance of Sentinel Lymph Node Biopsy
Sign Up to like & getrecommendations! Published in 2020 at "AntiCancer Research"
DOI: 10.21873/anticanres.14022
Abstract: Background/Aim: Among the most important prognostic factors in melanoma is the sentinel lymph node (SLN) status. Materials and Methods: Using our electronic database we identified 109 of 890 SLN-negative patients with progressive disease (PD). These… read more here.
Keywords: biopsy; group; progressive disease; sentinel lymph ... See more keywords
Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer
Sign Up to like & getrecommendations! Published in 2021 at "In Vivo"
DOI: 10.21873/invivo.12449
Abstract: Background/Aim: Rapid tumor growth after administration of immune checkpoint inhibitors is designated hyper progressive disease (HPD). In this study, besides the conventional HPD category, we proposed the “super HPD” category where the disease is naturally… read more here.
Keywords: advanced gastric; gastric cancer; disease; progressive disease ... See more keywords